GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » 3-Year FCF Growth Rate

BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) 3-Year FCF Growth Rate : 14.60% (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals 3-Year FCF Growth Rate?

BioCryst Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.05.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 14.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 7.00% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -5.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of BioCryst Pharmaceuticals was 30.90% per year. The lowest was -53.30% per year. And the median was 3.30% per year.


Competitive Comparison of BioCryst Pharmaceuticals's 3-Year FCF Growth Rate

For the Biotechnology subindustry, BioCryst Pharmaceuticals's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCryst Pharmaceuticals's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's 3-Year FCF Growth Rate falls into.



BioCryst Pharmaceuticals 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


BioCryst Pharmaceuticals  (NAS:BCRX) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


BioCryst Pharmaceuticals 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Executives
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Jon P Stonehouse director, officer: CEO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Charles K Gayer officer: Vice President and CCO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Michael L Jones officer: Exec Director, Finance - PAO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes officer: VP, General Counsel & Corp Sec 1929 BRASSFIELD ROAD, RALEIGH NC 27614
Anthony Doyle officer: Chief Financial Officer 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu officer: VP Drug Discovery 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
George B Abercrombie director C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
William P Sheridan officer: SR VP - CMO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Amy E Mckee director 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Lee Kenneth B Jr director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Steven K Galson director C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703

BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Headlines

From GuruFocus

BioCryst to Present at Upcoming Investor Conference

By sperokesalga sperokesalga 06-01-2023